Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017


My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Bayer gains full Vitrakvi rights from Eli Lilly's Loxo

share with twitter share with LinkedIn share with facebook
share via e-mail
02/15/2019 | 11:43am EST
Orchid stands on a table at the entrance to Loxo Oncology headquarters in Stamford

FRANKFURT (Reuters) - German drugmaker Bayer took full control of Vitrakvi, a drug used against a variety of cancers driven by a rare genetic mutation, in a deal with from Eli Lilly's Loxo Oncology.

Bayer said on Friday it exercised a right to gain exclusive licensing rights for the global development and commercialization of Vitrakvi, also known as larotrectinib, under a clause in the initial collaboration deal with Loxo Oncology that provided for Loxo becoming a takeover target.

Eli Lilly agreed to buy Loxo for $8 billion (£6.3 billion) in January and the deal was wrapped up on Friday.

Bayer has been called on by analysts and investors to strengthen its drug development pipeline as its pharmaceuticals division faces falling sales from 2024 amid looming competition for its two bestselling drugs.

Bayer clinched the initial Vitrakvi deal in November 2017, about a year before the drug eventually won U.S. regulatory approval, marking a bright spot in Bayer's development pipeline which has suffered a number of setbacks.

Shares in the German company, which also owns seed maker Monsanto, jumped on Friday and were up 4.4 percent at 68.44 euros at 1543 GMT. The stock has been dragged lower by litigation risks as thousands of U.S. plaintiffs claim its Roundup weed-killer played a role in their cancer.

Financial terms such as the initially agreed upfront payments to Loxo as well as milestone payments for development achievements remain unaffected, said a Bayer spokeswoman.

Vitrakvi, which is set to compete with Roche's entrectinib, has been shown to shrink tumours in 81 percent of cases across 24 tumour types in different parts of the body, all driven by a rare gene anomaly known as NTRK fusion.

Commercial success will depend on the fast uptake of comprehensive gene-sequencing tools for tissue samples at cancer units to help identify the cases that benefit from Vitrakvi.

Bayer has put the drug's annual peak sales potential at more than 750 million euros ($844 million).

The change-of-control option exercised by Bayer also covers the experimental compound LOXO-195, also known as BAY 2731954, which is designed to treat patients whose cancers are returning after an initial Vitrakvi treatment.

Rather than co-promote with Loxo in the U.S., as initially agreed, Bayer will commercialize the drug there exclusively.

The sharing of U.S. commercial costs and profits in equal parts will be replaced by royalties to be paid by Bayer, the company said, without specifying financial terms.

The German drugmaker will continue to pay royalties on future net sales outside the U.S.

(Reporting by Ludwig Burger; Editing by Tassilo Hummel and Elaine Hardcastle)

By Ludwig Burger

Stocks mentioned in the article
ChangeLast1st jan.
BAYER -0.53% 67.8 Delayed Quote.12.55%
ELI LILLY AND COMPANY -0.24% 122.12 Delayed Quote.5.84%
LOXO ONCOLOGY INC -0.03% 234.66 End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER
02/15Bayer gains full Vitrakvi rights from Eli Lilly's Loxo
02/12How a Philippines regulator stymied DowDuPont's global seed launch
02/11Sources Say Monsanto Wins Arbitration Ruling in India Seed Dispute -- Reuters
02/11EXCLUSIVE : Bayer's Monsanto wins arbitration ruling over royalties from Indian ..
02/08EXCLUSIVE : Brazil soy farmers say Bayer violating court ruling in patent disput..
02/07Bayer CropScience Q3 profit up over twofold
02/06BAYER : French, German farmers destroy crops after GMOs found in Bayer seeds
02/06BAYER : Return of French farmer's case keeps Monsanto in legal spotlight
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
02/05BAYER CROPSCIENCE LIMITED : reports Q3 results
More news
Financials (€)
Sales 2018 39 275 M
EBIT 2018 7 257 M
Net income 2018 4 936 M
Debt 2018 38 407 M
Yield 2018 4,12%
P/E ratio 2018 12,70
P/E ratio 2019 14,66
EV / Sales 2018 2,60x
EV / Sales 2019 2,16x
Capitalization 63 563 M
Duration : Period :
Bayer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 90,7 €
Spread / Average Target 33%
EPS Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER12.55%71 793
JOHNSON & JOHNSON5.68%365 768
PFIZER-2.86%245 920
ROCHE HOLDING LTD.12.28%233 628
NOVARTIS7.14%228 516